











































Effects of intrauterine insulin-like growth factor-1 therapy for
fetal growth restriction on adult metabolism and body
composition are sex specific
Citation for published version:
Spiroski, A, Oliver, MH, Jaquiery, AL, Gunn, TD, Harding, JE & Bloomfield, FH 2020, 'Effects of intrauterine
insulin-like growth factor-1 therapy for fetal growth restriction on adult metabolism and body composition are
sex specific', AJP - Endocrinology and Metabolism, vol. 318, no. 4, pp. E568-E578.
https://doi.org/10.1152/ajpendo.00481.2019
Digital Object Identifier (DOI):
10.1152/ajpendo.00481.2019
Link:




AJP - Endocrinology and Metabolism
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Adult effects of fetal IGF1 therapy for FGR 
1 
Effects of intrauterine insulin-like growth factor-1 therapy 1 
for fetal growth restriction on adult metabolism and body 2 
composition are sex-specific 3 
 4 
Ana-Mishel Spiroski P1P, Mark Hope OliverP1P, Anne Louise JaquieryP1P, Travis Dane 5 




PThe Liggins Institute, University of Auckland, Auckland, New Zealand 8 
 9 
Running title: Adult effects of fetal IGF1 therapy for FGR 10 
 11 
 12 
* Correspondence:  13 
Professor Frank H. Bloomfield 14 
Liggins Institute 15 
University of Auckland 16 
Private Bag 92019 17 
Auckland, New Zealand 18 
Tel: +64 9 923 6107 19 
Email: f.bloomfield@auckland.ac.nz  20 
Adult effects of fetal IGF1 therapy for FGR 
2 
Abstract 21 
Fetal growth restriction (FGR) is associated with compromised growth and metabolic 22 
function throughout life. Intrauterine therapy of FGR with intra-amniotic insulin-like 23 
growth factor-1 (IGF1) enhances fetal growth and alters perinatal metabolism and 24 
growth in a sex-specific manner, but the adult effects are unknown. We investigated 25 
the effects of intra-amniotic IGF1 treatment of FGR on adult growth and body 26 
composition, adrenergic sensitivity, and glucose-insulin axis regulation. Placental 27 
embolisation-induced FGR was treated with 4 weekly doses of 360 µg intra-amniotic 28 
IGF1 (FGRI) or saline (FGRS). Offspring were raised to adulthood (18 months: FGRI, 29 
n=12 females, 12 males; FGRS, n=13 females, 10 males) alongside offspring from un-30 
embolised and untreated sheep (CON; n=12 females, 21 males). FGRI females had 31 
increased relative lean mass compared with CON but not FGRS (p<0.05; 70.6±8.2% 32 
vs. 61.4±8.2% vs. 67.6±8.2%), decreased abdominal adipose compared with CON 33 
and FGRS (p<0.05; 43.7±1.2% vs. 49.3±0.9% vs. 48.5±1.0%), increased glucose 34 
utilisation compared with FGRS but not CON (p<0.05; 9.6±1.0 vs. 6.0±0.9 vs. 7.6±0.9 35 
mg·kgP-1P·minP-1P), and increased β-hydroxybutyric acid:non-esterified fatty acid ratio in 36 
response to adrenaline compared with CON and FGRS (p<0.05; 3.9±1.4 vs. 1.1±1.4 37 
vs. 1.8±1.4). FGRS males were smaller and lighter compared with CON but not FGRI 38 
(p<0.05; 86.8±6.3 vs. 93.5±6.1 vs. 90.7±6.3 kg), with increased peak glucose 39 
concentration (10%) in response to a glucose load, but few other differences. These 40 
effects of intra-amniotic IGF1 therapy on adult body composition, glucose-insulin axis 41 
function, and adrenergic sensitivity could indicate improved metabolic regulation 42 
during young adulthood in female FGR sheep. 43 
Keywords: Fetal therapy, intrauterine intervention, fetal programming, insulin 44 
sensitivity, adrenergic sensitivity, metabolism  45 
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Introduction 46 
Fetal deprivation results in altered in utero metabolic function that subsequently 47 
increases the risk of adult metabolic dysfunction (40). Fetal growth restriction (FGR), 48 
a failure to attain intrauterine growth potential (21), overlaps, but is not synonymous 49 
with, small-for-gestational age (SGA), a statistical definition of growth (usually 50 
birthweight ≤10PthP centile). The SGA neonate has increased peripheral insulin 51 
sensitivity at birth (15, 25) and glucose disposal at 48 hours of age (2). However, small 52 
size at birth and thinness often are followed by accelerated postnatal growth (3). This 53 
growth pattern, even over the first year after birth, is associated with decreased insulin 54 
sensitivity at one year (49) and increased visceral adiposity in later childhood (10, 42, 55 
48), and early adulthood (30). 56 
Metabolic dysfunction and rapidly increasing fat deposition increase the risk for non-57 
communicable diseases (NCDs) in adulthood (20). Decreased insulin sensitivity in 58 
adults with low birth weight is reportedly due to decreased insulin secretory capacity 59 
(28), insulin-stimulated glucose uptake (23), and insulin-signaling in skeletal muscle 60 
(27, 45). Studies in sheep suggest that FGR also leads to pancreatic β-cell dysfunction 61 
(22).  62 
FGR has been well studied in sheep, with substantial data indicating physiologic and 63 
molecular mechanisms of adaptation during fetal life (38). These studies suggest that 64 
the metabolic effects of FGR seen in postnatal life have their origins before birth, 65 
including decreased pancreatic β-cell mass and insulin secretion (32, 33). Thus, the 66 
optimal time for an intervention to prevent the long-term metabolic sequelae of FGR 67 
may be before birth. However, there are currently no effective clinical therapies for 68 
FGR. Therapies with potential from animal studies include maternal sildenafil citrate 69 
(16, 44) and intra-amniotic insulin-like growth factor (IGF)-1 (5, 6, 11, 17, 51, 53).  70 
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Weekly intra-amniotic IGF1 injection (360 µg·d P-1P) from 110-124 days’ gestation (term 71 
145) increases fetal growth trajectory and mRNA expression of placental amino acid 72 
transporters in the FGR sheep without any adverse perinatal effects (51, 53). We 73 
previously have reported that growth-altering effects of this brief fetal intervention 74 
persist into the immediate postnatal period in a sex-specific manner (51). However, 75 
the long-term effects through to adulthood are unknown. Thus, the aim of this study 76 
was to investigate the effect of intra-amniotic IGF1 treatment of the growth-restricted 77 
ovine fetus on growth, body composition and metabolism from the early postnatal 78 
period through to early adulthood (18 months). We hypothesised that intra-amniotic 79 
IGF1 treatment would normalise postnatal growth, body composition and metabolism 80 
compared with saline-treated control fetuses and that effects would differ in a sex-81 
specific manner. 82 
 83 
Materials and Methods 84 
All experimental procedures were approved by the University of Auckland Animal 85 
Ethics Committee (AEC/02/2008/R628 and AEC/03/2011/R874). Reporting of this 86 
experiment conforms with the ARRIVE Guidelines (29). The primary outcome for the 87 
experiment was glucose tolerance at 18 months of age. Based on previous studies in 88 
young adult sheep, we calculated that to detect a change in mean glucose area 89 
under the curve in a glucose tolerance test of 15% from 712 (SD 99) mmol·min−1·L−1, 90 
with 80% power and a 2-tailed significance level of 0.05, 12 successful studies were 91 
required per experimental group. Given that the outcomes being assessed (growth, 92 
body composition and glucose-insulin axis function) are known to differ between 93 
females and males, we determined a priori to analyse data separately by sex. We 94 
therefore required 12 successful studies per sex per experimental group.  95 
Adult effects of fetal IGF1 therapy for FGR 
5 
Animals were produced as previously described (51). Briefly, FGR was induced in 96 
sheep fetuses from 103-107 dGA by bilateral maternal uterine artery embolisation, 97 
twice daily titrated to fetal blood gases. Randomly allocated FGR fetuses received 98 
either sterile saline (FGRS) or 360 μg (100 μg·mL P-1P recombinant human IGF1 (FGRI; 99 
Genentech, San Francisco, California) by weekly intra-amniotic injection 107-135 100 
dGA. Numbers of pregnant ewes, fetal and perinatal losses resulting in the offspring 101 
numbers reported in this paper are detailed in the previous publication. 102 
 103 
Animal husbandry. At two weeks of age, individually housed ewe-lamb pairs were 104 
transitioned into a mob. At three weeks of age a rubber ring was applied to dock the 105 
tail, and lambs were transferred with their dams onto pasture. Lambs were weaned 106 
and split into same-sex mobs at 3 months of age (males were not castrated) and 107 
maintained on pasture until 17-18 months of age (early adulthood, puberty is ~7-8 108 
months). At 4, 12, and 17-18 months sheep were brought into the feedlot where they 109 
were housed individually but with direct contact with, and in the sight and sound of, 110 
other sheep. 111 
 112 
Weight and linear measures. Weight, crown-rump length (CRL), abdominal 113 
circumference, and hock-to-toe length (HT), were measured at two and three weeks, 114 
and monthly thereafter. Growth velocity for weight and linear measures were 115 
calculated as described previously (51). Relative weight per unit body length was 116 
calculated as body mass index (BMI, kg·CRL P-2P). 117 
 118 
Blood sampling, hormone and metabolite analyses. Blood samples were collected via 119 
venipuncture at 2, 3 and 4 weeks, and at 2 and 3 months. Throughout the physiologic 120 
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testing procedures blood was collected via indwelling catheters (26). Whole blood 121 
glucose concentration was measured on a YSI 2300 (Yellow Springs Instruments, 122 
Queensland, AU). Blood samples were centrifuged at 3,220 g, 4°C for 10 minutes and 123 
plasma was stored at -80°C until biochemical analysis. 124 
Plasma metabolite (glucose, non-esterified fatty acid (NEFA), urea and β-125 
hydroxybutyric acid (βHBA)) concentrations were measured on a Hitachi 902 126 
autoanalyser (Hitachi High-Technologies Corporation, Tokyo, Japan) as described 127 
previously (51). Mean inter- and intra-assay coefficients of variation (CV), respectively, 128 
were 4.3% and 3.8% for urea; 3.4% and 2.4% for NEFA; 4.0% and 1.1% for βHBA, 129 
and the mean intra-assay CV for glucose was 1.6%. 130 
Plasma insulin was measured by radioimmunoassay (RIA) with ovine insulin (Sigma-131 
Aldrich, St. Louis, Missouri, USA) as the standard (41). The minimum level of detection 132 
was 0.03 ng·mL P-1P. Mean inter- and intra-assay CVs were 8.6% and 11.7%, 133 
respectively. 134 
 135 
Dual X-ray absorptiometry (DXA). Animals were sedated for DXA scans (Norland, XR-136 
800, Cooper Surgical Ltd, Fort Atkinson, WI, USA) at 4, 12 and 18 months of age. 137 
Sedation was induced with intravenous 5.0 mg·kgP-1P ketamine and 0.25 mg·kg P-1P 138 
diazepam (Parnell Co. Ltd. and Ceva Animal Health Ltd., respectively, Auckland, NZ) 139 
and maintained with 10.0 mg·kg P-1P ketamine and 0.5 mg·kg P-1P diazepam. Palpebral 140 
reflex and arousal state were monitored, and sedation titrated as needed.  141 
At 4 months DXA scans were conducted as described previously (51). At 12 and 18 142 
months, scans were undertaken at a spatial resolution of 6.0 x 6.0 mm. The area 143 
analysed was divided into three areas: chest; abdomen, and rump. The chest area 144 
was bounded by lines connecting the first cervical vertebra, the first lumbar vertebra, 145 
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the diaphragm, and the sternum and along the breast to include the heads of the radii 146 
and ulnae. The abdominal area was bounded by the chest area, the lumbosacral spine 147 
at the anterior line of the pelvis, along the anterior margin of the pelvic limb and around 148 
the ventral portion of the abdomen. The rump area was bounded by the abdominal 149 
area and included the base of the tail and the femorotibial joint. Fat and lean mass 150 
and bone mineral content were estimated using Norland software (Cooper Surgical 151 
Ltd, Fort Atkinson, WI, USA) and expressed in grams. Fat and lean mass of each area 152 
were calculated relative to both overall compartment mass and total bodyweight. 153 
 154 
Physiologic testing. To ensure ewes were not in estrus at the time of study, estrus was 155 
synchronised with an intravaginal controlled internal drug release device (CIDR; 156 
Pfizer, Auckland, NZ) containing 0.03 g progesterone.  Adult sheep were allocated to 157 
undergo adult physiologic testing using a random number generator. Sheep 158 
randomised not to receive tests were housed alongside those undergoing procedures 159 
throughout. Three days prior to testing, feed intake was titrated to allow 10% by weight 160 
feed refusal per day. Indwelling jugular venous catheters were inserted as described 161 
previously (26). and maintained with flushes of 10 U·mL P-1P sodium heparinised 0.9% 162 
sterile saline (sodium heparin, Hospira, Victoria, AU). Sheep underwent an 163 
intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp (HGC) following 164 
an overnight fast, and an epinephrine stimulation test (EPI) in the fed state. Animals 165 
were free-moving during the IVGTT and EPI, but were restrained within their pens 166 
using straps during the HGC, a necessary precaution due to the nature and duration 167 
of the test. 168 
 169 
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Intravenous glucose tolerance test. Following an overnight fast, 0.5 g·kgP-1P 50% 170 
dextrose was infused in ≤60 seconds and followed by a 10 mL 0.9% saline flush. Blood 171 
samples were collected at baseline, and 2, 5, 10, 15, 20, 30, 40, 50, 60, 120 and 180 172 
minutes post-bolus.  173 
 174 
Hyperglycemic clamp. Two days after the GTT and following an overnight fast, blood 175 
samples were taken at -20, -15, -10 and 0 minutes to determine basal whole blood 176 
glucose concentration, followed by a 7.7 mL·minuteP-1P·mP-2P body surface area (kg P0.67P x 177 
0.09 (36)) 25% dextrose bolus over 0-5 minutes to increase blood glucose 178 
concentration to 10 mmol·L P-1P. The rate of glucose infusion thereafter was adjusted 179 
according to a computer algorithm to maintain blood glucose concentration at a 10 180 
mmol·LP-1P steady state (SS). Blood samples were collected at 5-minute intervals 181 
through 135 minutes to determine whole blood glucose concentration; plasma was 182 
prepared from samples collected at 15-minute intervals for insulin assay. To maximize 183 
insulin secretion, a 100 mg·kg P-1P ˪-Arginine bolus was infused immediately following 184 
the 135-minute blood sample (4) followed by blood sample collection at 5-minute 185 
intervals to determine whole blood glucose concentration and plasma prepared from 186 
samples collected at 5, 10, 20, and 30 minutes post-bolus for insulin assay. HGC data 187 
were analysed if the blood glucose concentration coefficient of variance was ≤10% 188 
during SS (75-135 minutes). 189 
 190 
Analysis of glucose tolerance and insulin sensitivity. In the pre-weaning lambs from 2-191 
12 weeks of age, insulin secretion and sensitivity were assessed with the homeostasis 192 
model assessment (iHOMA2) of β-cell function (HOMA-%β) and insulin resistance 193 
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(HOMA-%S) from plasma glucose and insulin concentrations (24), and absolute 194 
change from 2-12 weeks was calculated. 195 
In adult sheep, glucose tolerance was assessed with IVGTT by calculating the areas 196 
under the curve (AUC) for glucose during the first (0-15 minutes) and second (15-180 197 
minutes) phases after the glucose bolus (mmol∙L P-1P; IVGTT-AUCRG1R and IVGTT-AUCRG2R, 198 
respectively) (46), the first phase insulin response (AIR R15R) (34, 43), change in insulin 199 
secretion from baseline in the first phase (ΔI RS1R), the second phase AUC for insulin 200 
(IVGTT-AUCRI2R) and insulin secretion relative to glucose during SS (IRSR, ng∙mLP-201 
1
P∙mmol∙LP-1P) (19).  202 
Pancreatic β-cell function in the adult was assessed with HGC; insulin AUC (HGC-203 
AUCRIR) was calculated using the trapezoidal rule from baseline to the end of SS (HGC-204 
AUCRISSR) and following the ˪ -Arginine bolus to completion of the clamp (HGC-AUCRIARGR). 205 
We calculated mean glucose infusion during SS (IGRSSR: mmol·kgP-1P·minP-1P) and following 206 
the ˪-Arginine bolus (IGRARGR: mmol·kgP-1P·minP-1P), mean plasma insulin concentration 207 
during SS (IRSSR: ng·mLP-1P), peak plasma insulin concentration following the ˪-Arginine 208 
bolus (IRARGR: ng·mLP-1P), the change in insulin secretion from SS in response to the ˪-209 
Arginine bolus (ΔIRSR ARG:SS), insulin sensitivity during SS (SRiR SS= IG RSSR/IRSSR) and 210 
following the ˪-Arginine bolus (SRiR ARG= IGRARGR/IRARG R) (37), the insulin-dependent 211 
component of whole-body glucose tolerance during SS, the glucose disposition index 212 
(DIRGR = SRiR SS x AIRR15R) (34), and glucose-stimulated insulin secretion (Mean IRSSR/basal 213 
plasma insulin) (7, 31). 214 
 215 
Epinephrine stimulation test. After collecting a baseline blood sample, 1.0 µg·kgP-1P 216 
epinephrine (Mayne Pharma, Salisbury South, South Australia, AU) was injected 217 
intravenously followed by a 10 mL 0.9% saline flush. Blood samples were collected at 218 
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2.5, 5, 7.5, 10, 15, 20, 30, 45 and 60 minutes.  Adrenergic responsiveness was 219 
assessed by calculating the AUC for plasma glucose, βHBA, and NEFA in the first 220 
phase post-injection (first 7.5 minutes: EPI-AUCRG7.5R, EPI-AUCRNEFA7.5R, and EPI-221 
AUCRβHBA7.5R), peak response, and glucose and βHBA relative to NEFA response at 7.5 222 
minutes. 223 
 224 
Post-mortem. All post-mortems were conducted following an overnight fast. In sheep 225 
randomised to receive physiologic tests, post mortems were conducted 5-6 days after 226 
completion of testing to allow adequate time for recovery and drug elimination, and 227 
those of untested adult sheep were conducted in parallel. Live weight was collected, 228 
and sheep euthanised with a 100-120 mg·kgP-1P sodium pentobarbitone injection. Total 229 
adrenal, brain, cerebellum, heart, total kidney, liver, total lung, pancreas, pancreatic 230 
lymph node, total perirenal fat, neck thymus, and thyroid weights were collected. Fat 231 
depth was measured at the 12PthP rib on the left side of the carcass, (9), and empty 232 
carcass was weighed.   233 
 234 
Statistical analysis. Data were analysed in JMP 12 (SAS Institute Inc., Cary, North 235 
Carolina, USA) and GraphPad Prism 7.0 (La Jolla, California, USA). Distribution was 236 
verified with the Shapiro-Wilk test. Non-normally-distributed data were log transformed 237 
to approximate a normal distribution where necessary. The effects of FGR and intra-238 
amniotic treatment of FGR with IGF1 were analysed by factorial or repeated measures 239 
analysis of variance (ANOVA and RM ANOVA, respectively) in each sex with breeding 240 
year as a random effect. RM ANOVA was used to examine changes over time. 241 
Correlations were assessed by linear regression analysis separately for each sex. 242 
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Significance was set at p<0.05 unless otherwise stated. Tukey’s post hoc testing was 243 
conducted where appropriate. Results are presented as mean ± SEM. 244 
 245 
Results 246 
Animal numbers and losses throughout the study. Ninety-eight sheep survived to two 247 
weeks of age and entered the study (Supplementary Figure 1) (51). Postnatal mortality 248 
was low and not different amongst groups (Supplementary Table 1). For perinatal 249 
outcomes, see Spiroski, 2017. Briefly, FGR lambs were ~20% lighter at birth, and IGF1 250 
treatment partially reversed the reduced size at birth in females, and reduced FGR-251 
mediated acceleration in growth velocity in both sexes. 252 
 253 
Pre-weaning linear growth. In females, FGRI had reduced CRL compared with CON 254 
at weaning (p<0.05) and decreased pre-weaning GV of CRL (FGRI 4.5±0.4; FGRS 255 
5.2±0.4; CON 5.6±0.4 g·kg P-1P·dP-1P; p<0.05 for FGRI vs CON) but similar weight, 256 
abdominal circumference and HT length. FGRS females had decreased CRL at 3 257 
weeks and HT at 4 weeks compared with CON (both, p<0.05), but these differences 258 
were no longer statistically significant at weaning (Figure 1, A-D).  259 
In males, FGRI lamb weight, CRL and abdominal circumference were less than CON 260 
initially, but by 4 weeks these measurements were similar amongst all three groups 261 
(Figure 1, E-G). FGRS and FGRI HT were less than CON at 4 weeks, but not thereafter 262 
(Figure 1H). 263 
There were no differences between FGRI and FGRS in any of these parameters 264 
(Figure 1). 265 
 266 
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Post-weaning linear growth. In females, FGRI and FGRS sheep had reduced CRL 267 
compared with CON from 4 through 15 months, and at 18 months in FGRI (all, p<0.05) 268 
(Figure 2, B). Similarly, in FGRI and FGRS sheep HT from 5 through 12 months, and 269 
abdominal circumference from 5 through 7 months also were less than in CON (all, 270 
p<0.05) but weight was not significantly different at any time (Figure 2, A-D).  271 
In males, weight was not different at any time and differences in linear growth were 272 
less marked, with HT length less in FGRI and FGRS than CON from 15 through 17 273 
months, and least in FGRS (p<0.05) (Figure 2, E-H).  274 
There were no differences in growth velocity for weight or linear growth amongst 275 
groups (data not shown). 276 
 277 
Body composition. In females, lean mass was decreased in both FGRI and FGRS at 278 
4 months of age compared with CON (p<0.05), and tended to be less in FGRS, but 279 
not FGRI, males (p=0.06). Bone mineral content also tended to be less in female 280 
(p=0.07), but not male, FGR compared with CON (Table 1). 281 
There were no differences amongst groups in DXA measures at 12 months of age in 282 
either sex (Supplementary Table 2). 283 
At 18 months of age in females FGRI had increased total lean mass relative to body 284 
weight (p<0.05) compared with CON, and increased rump lean mass compared with 285 
both CON and FGRS (p=0.05, p<0.05, respectively). However, abdominal lean mass 286 
in FGRI was less than CON and chest lean mass was decreased compared with both 287 
CON and FGRS (p<0.05). Accretion of lean mass between 4 and 18 months of age 288 
was greater in female FGRI and FGRS than in CON (p<0.05, Table 1).  289 
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FGRI females also had decreased abdominal fat mass relative to total fat mass than 290 
both CON and FGRS (p<0.05, Table 1). In males, body composition parameters at 18 291 
months were not different amongst groups. 292 
 293 
Post-mortem. Female FGRI sheep were lighter at PM than CON with lighter absolute 294 
and relative heart weight (relative to body surface area), lighter thyroid weight, but 295 
greater liver weight relative to live weight (all p<0.05) compared with CON. Female 296 
FGRS sheep had lighter cerebellae (p<0.05) compared to CON and lighter relative 297 
cerebellar weight compared with FGRI (p<0.05; Table 2). Male FGRS were lighter than 298 
CON with decreased carcass weight and lesser relative brain weight than CON 299 
(p<0.05; Table 2). 300 
 301 
Pre-weaning glucose and insulin sensitivity. In females, FGRI lambs had a greater 302 
reduction in HOMA-determined β-cell function, but not in HOMA-determined insulin 303 
resistance, from 2 weeks to weaning compared with both CON and FGRS (Figure 3, 304 
A-D). In males, there were no differences amongst groups (Figure 3, E-H); however, 305 
increased weight at weaning in FGRI and FGRS male lambs was associated with 306 
reduced pre-weaning β-cell function (Figure 4). There was no such relationship in male 307 
CON or in any of the female groups. 308 
 309 
Adult glucose and insulin sensitivity. In females, glucose and insulin response to an 310 
intravenous glucose tolerance test were not different amongst groups for any 311 
calculated measure (Table 3), although there was a significant time*experimental 312 
group interaction of insulin response over the entirety of the test, with CON having 313 
highest insulin concentrations (Figure 5). In the HGC, FGRS females had a 50% 314 
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reduction in mean glucose disposition compared with CON (p=0.06), required ~40% 315 
less glucose to maintain steady state compared with FGRI (p<0.05) with similar 316 
requirements to CON, but had no change in insulin secretion or insulin sensitivity. In 317 
males, FGRS sheep had poorer glucose tolerance compared to CON with increased 318 
peak plasma glucose during the IVGTT (Figure 5), increased peak change from 319 
baseline and decreased insulin secretion relative to glucose (all p<0.05; Table 3). 320 
There were no significant differences in males amongst groups during the HGC (Table 321 
4). 322 
 323 
Adult adrenergic sensitivity and lipid mobilisation. In females, there were no 324 
differences amongst groups in the first phase βHBA or NEFA responses to 325 
epinephrine but FGRI female sheep had an increased first phase Glucose:NEFA ratio 326 
(p<0.05) compared with CON and βHBA:NEFA ratio (p<0.05) compared with both 327 
FGRS and CON (Table 5). In males, FGRI had a blunted glucose response in 328 
response to epinephrine in the first 7.5 minutes compared with CON (p<0.05), but 329 
were not different from FGRS (Supplementary Figure 2; Table 5).  330 
In both females and males, in FGRI abdominal fat mass was positively correlated with 331 
peak first phase NEFA response (female: p<0.0001, male: p<0.008). These 332 
associations were weaker, and not statistically significant, in female CON and FGRS 333 
and in male FGRS and absent in male CON (Figure 7). 334 
 335 
Discussion 336 
Fetal growth restriction remains a significant clinical challenge in diagnosis, 337 
management, and the long-term consequences for the affected baby. Whilst various 338 
intrauterine therapies have been investigated in pre-clinical animal studies (50), 339 
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progression to clinical trials is limited due to a lack of efficacy. We previously have 340 
shown that intra-amniotic IGF1 treatment of the growth-restricted ovine fetus improves 341 
fetal growth, restores gut development and up-regulates placental amino acid 342 
transporters (5, 17, 53). We have also reported that this therapy does not result in 343 
increased perinatal morbidity or mortality, a potential concern when growth is improved 344 
in an environment of relative deprivation (51). However, IGF1 is a growth-promoting 345 
hormone and, therefore, long-term assessment of safety and efficacy is necessary. In 346 
this study we demonstrate that fetal treatment of growth restriction with low doses of 347 
intra-amniotic IGF1 improves body composition and alters metabolic flexibility in 348 
adulthood in a sexually dimorphic manner.  349 
Growth-restricted lambs caught up with respect to weight, but not linear growth, by 4 350 
months of age (post-weaning). Linear growth, as assessed by crown-rump length and 351 
hock-toe length, was similar to control animals by young adulthood. However, in both 352 
FGRI and FGRS males, greater weight at weaning was strongly correlated with a 353 
greater reduction in basal insulin secretion in the pre-weaning period. This suggests 354 
increased insulin sensitivity in growth-restricted offspring during the pre-weaning 355 
period, and is consistent with other paradigms of FGR in sheep (13, 39). This 356 
relationship was not evident in female lambs, but FGRI females had a greater 357 
reduction in basal insulin secretion compared to both FGRS and CON, which could 358 
suggest a compensatory adaptation to greater insulin sensitivity across the pre-359 
weaning period. The decreased acute insulin response, and greater requirement for 360 
glucose to maintain steady state during the hyperglycaemic clamp in adult female 361 
FGRI sheep compared with CON, could also suggest improved insulin sensitivity in 362 
IGF1-treated adult females. These persistent changes indicate that fetal IGF1 therapy 363 
beneficially influences metabolic health in the growth-restricted adult. 364 
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Previous observations in SGA children suggest that decreased pancreatic β-cell 365 
compensation is associated with increased propensity for visceral adipose deposition 366 
(35). We did not find increased abdominal adiposity in FGRS females compared with 367 
CON, despite a trend towards reduced glucose disposition and reduced lean mass; 368 
however, IGF1 therapy altered lean and fat mass compartmentalization in females, in 369 
particular reducing abdominal adipose. Abdominal obesity is associated with 370 
metabolic syndrome and cardiovascular disease risk (14). The selective reduction in 371 
abdominal adipose in female offspring has clinical implications in the long-term 372 
maintenance of cardiometabolic health in FGR offspring. In male FGRS sheep, the 373 
impaired glucose tolerance compared with CON despite a greater insulin response, 374 
and reduced insulin sensitivity compared to both CON and FGRI suggest that FGR in 375 
the male is associated with decreased peripheral sensitivity of glucose uptake to 376 
insulin, possibly due to reduced skeletal muscle insulin sensitivity (12). Interestingly, 377 
both live and empty carcass weight in FGRS males were significantly less than CON 378 
at post-mortem suggest a failure to catch-up, which is consistent with a recent meta-379 
analysis of human datasets demonstrating that low birth weight individuals may have 380 
a decreased risk of being overweight (47). Intra-amniotic IGF1 Intervention in males 381 
resulted in greater capacity for ʟ-Arginine-stimulated insulin secretion, which 382 
approaches significance when compared with FGRS. These data are compatible with 383 
the increased pancreatic insulin sequestration observed in the studies of Limesand 384 
and colleagues (33). Although a greater than 50% increase in insulin sensitivity in 385 
FGRI males compared with FGRS was not significant at this relatively young age, 386 
future studies should investigate whether manifest dysfunction in homeostatic control 387 
of the glucose-insulin axis due to FGR is corrected by intra-amniotic IGF1 treatment 388 
at a more advanced age.  389 
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Of significant interest are the sex-specific effects of this treatment on both metabolic 390 
regulation and body composition. Lesser abdominal adipose accumulation and a 391 
striking increase in lean mass from the pre- to post-pubertal period in females could 392 
suggest that the complex gonadotrophic and somatotrophic interactions which occur 393 
during puberty (52) may be altered by intra-amniotic IGF1 intervention. Increased lean 394 
tissue accretion could be due to greater skeletal muscle somatotrophic sensitivity, 395 
augmented by peripheral nutrient signalling pathways and glucose utilisation. 396 
Additionally, greater adrenergic sensitivity in FGRI-treated offspring could indicate a 397 
shift in substrate mobilization during periods of stress. These data suggest that intra-398 
amniotic IGF1 intervention of the growth-restricted fetus recovers growth restriction-399 
mediated adrenergic desensitisation (8), and have significant implications for the 400 
maintenance of age-appropriate body composition and metabolic regulation in FGR 401 
adults at risk for the development of NCDs.  402 
Interestingly, FGRI sheep of both sexes show a strong positive correlation between 403 
abdominal fat mass at 18 months and peak adrenaline-stimulated plasma NEFA 404 
concentration, suggesting that mobilisation is appropriate to abdominal substrate 405 
sequestration. Unfortunately, from the current data we cannot determine the primary 406 
origin of adrenergic-stimulated lipolysis or glycogenolysis. Molecular analyses of 407 
adrenergic receptor expression and tissue-specific glycolytic, lipolytic, and oxidative 408 
capacity are required to determine whether intra-amniotic IGF-1 treatment contributes 409 
to substrate selection and metabolic capacity, which is impaired in the growth-410 
restricted lamb (8, 54). If abnormal depot-specific tissue accretion, which is evident in 411 
the liver of FGR and SGA humans (1, 18), is corrected with intra-amniotic IGF1-412 
intervention, this could be associated with the recovery of an appropriate metabolic 413 
phenotype.  414 
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 415 
Perspectives and Significance 416 
We report significant improvement in adult metabolic function and body composition 417 
after intra-amniotic treatment of FGR. This is the first study to demonstrate persistent, 418 
beneficial, long-term effects of a prenatal intervention. However, metabolic testing in 419 
young adulthood may be too early to identify long-term effects of the intervention and 420 
physiological significance. Indeed, as insulin sensitivity and secretion wane with 421 
ageing, studies in later life would help determine whether these findings become more 422 
apparent with age and, therefore, the potential of this prenatal intervention to 423 
preventing chronic diseases of ageing should the findings translate to the human. Our 424 
study extends previous knowledge about sexually dimorphic adaptations to FGR and 425 
intra-amniotic IGF1 intervention in the newborn period by showing that these persist 426 
and develop through 18 months of age in the placental insufficiency-induced growth-427 
restricted sheep. Further work is needed to elucidate whether these sex-specific 428 
responses are due to an improved prenatal environment, or compensatory adaptations 429 
to the intervention in later life. 430 
The burgeoning increase in NCDs such as metabolic syndrome, diabetes, 431 
cardiovascular diseases, and obesity, indicate that current preventative interventions 432 
are inadequate. However, this work provides proof-of-principle that a brief fetal 433 
intervention has long-term sex-specific effects in fetal growth restricted offspring. We 434 
demonstrate that early-life intervention, before the progression to symptomatic 435 
metabolic dysfunction in early adulthood, improves clinically relevant aspects of 436 
growth and metabolism.  437 
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Figure Legends 459 
Figure 1. Postnatal growth to weaning. Weight, crown rump length (CRL), 460 
abdominal circumference, and hock-to-toe (HT) length in female (A-D) CON (white, 461 
n=14), FGRS (grey, n=15), FGRI (black, n=13), and male (E-H) CON (white, n=22), 462 
FGRS (grey, n=12), FGRI (black, n=18) lambs from 2-12 weeks of age. Data are mean 463 
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± SEM. Symbols denote p-values for differences between experimental groups at each 464 
time point (ANOVA: * FGRS vs. CON, p<0.05; † FGRI vs. CON, p<0.05). 465 
 466 
Figure 2. Postnatal growth from weaning to adulthood. Weight, crown rump length 467 
(CRL), abdominal circumference, and hock-to-toe (HT) length in female (A-D) CON 468 
(white, n=12), FGRS (grey, n=14), FGRI (black, n=13), and male (E-H) CON (white, 469 
n=21), FGRS (grey, n=10), FGRI (black, n=12) sheep from 4 to 18 months of age. 470 
Data are mean ± SEM. Symbols denote p-values for differences between experimental 471 
groups at each time point (ANOVA: * FGRS vs. CON, p<0.05; † FGRI vs. CON, 472 
p<0.05; ‡ FGRI vs. FGRS, p<0.05). 473 
 474 
Figure 3. Postnatal Homeostasis Model of Assessment through weaning. 475 
Homeostasis Model of Assessment of β-cell function (HOMA%-β) and insulin 476 
sensitivity (HOMA-%S) from 2-12 weeks of age, and the change in HOMA-β and 477 
HOMA-S from 2-12 weeks in: (A-D) female CON (white, n=12), FGRS (grey, n=9) and 478 
FGRI (black, n=12), and (E-H) male CON (white, n=15), FGRS (grey, n=11) and FGRI 479 
(black, n=9) lambs. Data are mean ± SEM. Symbols denote p-values for differences 480 
between experimental groups at each time point (ANOVA: † FGRI vs. CON, p<0.05; 481 
‡ FGRI vs. FGRS, p<0.05). 482 
 483 
Figure 4. The change in β-cell function through weaning relative to weaning 484 
weight in males. The correlation between the change in Homeostatic Model of 485 
Assessment of β-cell function (HOMA-%β) from 2-12 weeks of age, and weight at 486 
weaning (12 weeks) in male CON (white and dotted line, n=15), FGRS (grey, n=11) 487 
and FGRI (black, n=9) lambs. Significant correlations are indicated. 488 
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 489 
Figure 5. Glucose tolerance in adulthood. Plasma glucose and insulin response to 490 
an intravenous glucose tolerance test in female (A, B) CON (white, n=7), FGRS (grey, 491 
n=10) and FGRI (black, n=9) and male (C, D) CON (white, n=9), FGRS (grey, n=9) 492 
and FGRI (black, n=8) sheep. Data are mean ± SEM. Roman numerals denote the 493 
significant difference between experimental groups (RM ANOVA: iii, 494 
time*experimental group interaction p<0.05). SEM. Symbols denote p-values for 495 
differences between experimental groups at each time point (ANOVA: * CON vs. 496 
FGRS, p<0.05). 497 
 498 
Figure 6. Glucose-stimulated insulin regulation in adulthood. Plasma glucose 499 
(circles) and insulin (squares) response to an intravenous hyperglycemic clamp with 500 
period of steady state hyperglycemia (SS) and following an L-arginine bolus (ARG) in 501 
female (A) CON (white, n=8), FGRS (grey, n=9) and FGRI (black, n=9) and male (B) 502 
CON (white, n=8), FGRS (grey, n=7) and FGRI (black, n=7) sheep. Data are mean ± 503 
SEM. Roman numerals denote the significant difference between experimental groups 504 
(RM ANOVA: i, main effect of experimental group, p<0.05; ii, effect of time, p<0.05; iii, 505 
time*experimental group interaction, p<0.05). Symbols denote p-values for differences 506 
between experimental groups at each time point (ANOVA: ‡ FGRS vs. FGRI, p<0.05). 507 
 508 
Figure 7. Correlation between peak plasma non-esterified fatty acid response to 509 
epinephrine and abdominal fat. The correlation between peak plasma non-esterified 510 
fatty acid (NEFA) concentration following an epinephrine stimulation test and 511 
abdominal fat by dual X-ray absorptiometry in female (A) CON (white and dotted line, 512 
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n=9), FGRS (grey, n=11) and FGRI (black, n=10), and male (B) CON (white and dotted 513 
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 Female  Male  
Significance 
(treatment effect) 













 Female Male 
BMC (g) 402±41 353±41 360±42  384±11 374±18 392±20  0.07* ns 
BMD (g·cmP-2P) 0.99±0.05 0.91±0.04 0.94±0.05  0.91±0.03 0.95±0.04 0.95±0.04  ns ns 
LM (kg) 28.6±2.0 25.8±2.0 25.3±2.0  31.4±1.0 28.9±1.2 29.9±1.1  <0.05*† 0.06* 















   
BMC (kg)  1.3±0.2 1.2±0.2 1.1±0.2  1.3±0.1 1.2±0.1 1.4±0.1  ns 0.08‡ 
Chest LM (kg) 15.0±0.3 15.2±0.3 13.5±0.4  20.8±1.0 19.2±1.1 20.6±1.0  <0.05†‡ ns 
Chest FM (kg) 6.1±1.7 5.3±1.7 4.6±1.7  3.3±0.9 2.7±1.0 3.1±1.0  ns 0.07* 
Abdominal LM (kg) 24.7±0.5 24.1±0.5 22.2±0.9  31.1±1.9 30.1±2.0 29.4±2.0  0.05† ns 
Abdominal FM (kg) 10.0±2.8 8.5±2.8 7.9±2.8  5.1±1.5 4.3±1.6 4.5±1.6  ns ns 
Rump LM (kg) 10.5±1.1 10.4±1.2 16.1±1.6  13.9±0.6 15.7±0.9 13.4±1.1  0.05†, <0.05‡ ns 
Rump FM (kg) 4.2±1.0 4.4±1.0 5.0±1.0  2.5±0.4 2.0±0.4 2.4±0.4  ns ns 
Total LM (%) 50.4±1.3 50.1±1.3 52.8±1.0  67.6±1.6 65.5±2.0 64.3±2.0  ns ns 
Total FM (%) 20.3±5.9 18.2±5.9 18.7±5.9  11.0±3.0 9.0±3.0 9.7±3.0  ns ns 
LM:WT (%) 61.4±8.2 67.6±8.2 70.6±8.2  71.1±2.8 73.0±3.0 71.0±3.0  <0.05† ns 
FM:WT (%) 24.1±5.0 23.1±4.9 23.8±5.1  11.8±2.1 9.9±2.2 11.2±2.2  ns ns 
Abdominal FM:WT (%) 11.9±2.4 10.8±2.4 10.0±2.4  5.4±1.2 4.7±1.3 4.9±1.3  ns ns 
Abdominal FM:Total FM (%) 49.3±0.9 48.5±1.0 43.7±1.2  46.0±2.0 46.1±2.2 45.8±2.1  <0.05†‡ ns 
GVR4-18R LM (g·kgP-1P·dP-1P) 1.4±0.3 1.8±0.3 1.8±0.3  1.9±0.1 2.0±0.1 2.1±0.1  <0.05*† ns 
Table 1. Body composition at 4 and 18 months of age. Bone mineral content (BMC), compartmental and total lean mass (LM) and fat mass (FM), 
absolute and, where appropriate, relative to weight (WT); growth velocity of lean mass from 4-18 months of age (GV R4-18R LM). Data are mean ± SEM. 
Symbols denote differences amongst experimental groups on post hoc testing: * FGRS vs. CON; † FGRI vs. CON; ‡ FGRI vs. FGRS. 
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 Female Male 
Live Weight (kg) 83.8±6.9 78.8±6.9 76.7±6.9  93.5±6.1 86.8±6.3 90.7±6.3  <0.05† <0.05* 
Carcass Weight (kg) 54.7±4.0 52.9±4.0 49.8±4.0  60.1±2.6 54.9±2.8 59.5±2.8  ns <0.05* 
Fat Depth, 12th Rib (mm) 22.9±3.4 21.0±3.3 19.0±3.4  16.3±2.9 14.5±3.1 12.8±3.0  ns ns 
Adrenals (g) 5.3±0.3 4.8±0.3 5.7±0.3  5.6±0.2 5.2±0.3 5.2±0.2  ns ns 
Brain (g) 106±3 102±3 102±3  110±2 115±2 111±2  ns ns 
Cerebellum (g) 11.8±0.5 10.9±0.5 11.6±0.5  13.1±0.1 13.0±0.3 13.0±0.2  <0.05* ns 
Heart (g) 329±16 305±16 299±16  377±16 368±19 354±18  <0.05† ns 
Kidneys (g) 230±10 209±10 219±11  279±11 280±13 292±13  ns ns 
Liver (g) 1,352±80 1,310±80 1,368±82  1,623±112 1,578±121 1,601±118  ns ns 
Lungs (g) 628±49 617±48 617±49  753±21 689±27 646±26  ns ns 
Pancreas (g) 97±7 81±6 86±7  103±4 101±5 113±5  ns ns 
Pancreatic Lymph Node (g) 1.6±0.3 2.2±0.3 2.3±0.3  2.7±0.2 2.1±0.3 1.8±0.3  ns <0.05† 
Perirenal Fat (g) 1,061±152 1,072±150 932±154  505±73 442±79 419±78  ns ns 
Thymus, neck (g) 32.9±7.0 30.6±6.6 35.5±6.9  20.5±4.8 23.2±5.5 23.5±5.3  ns ns 
Thyroid (g) 10.6±1.3 9.1±1.3 7.2±1.4  9.4±1.6 9.1±1.6 7.7±1.6  <0.05† ns 
Brain:WT (%) 0.13±0.01 0.13±0.01 0.14±0.01  0.12±0.01 0.13±0.01 0.12±0.01  ns <0.05* 
Cerebellum:WT (%) 0.014±0.001 0.014±0.001 0.015±0.001  0.014±0.001 0.015±0.001 0.015±0.001  <0.05‡ ns 
Heart WT:BSA (g·mP-2P) 2,719±123 2,529±121 2,486±123  3,084±109 3,031±133 2,943±132  <0.05† ns 
Kidney:WT (%) 0.27±0.01 0.27±0.01 0.29±0.01  0.30±0.01 0.30±0.01 0.31±0.01  ns ns 
Liver:WT (%) 1.62±0.06 1.67±0.06 1.81±0.06  1.73±0.02 1.86±0.05 1.78±0.03  <0.05† ns 
Pancreas:WT (%) 0.12±0.01 0.10±0.01 0.12±0.01  0.11±0.01 0.12±0.01 0.12±0.01  ns ns 
BMI (kg·mP-2P) 63.3±6.5 61.8±6.5 62.1±6.5  65.8±6.6 65.2±6.7 64.2±6.7  ns ns 
Table 2. Post mortem carcass and organ weights and measures. Live weight (WT), body surface area (BSA), body mass index (BMI). Data are mean ± 
SEM. Symbols denote differences amongst experimental groups on post hoc testing: * FGRS vs. CON; † FGRI vs. CON; ‡ FGRI vs. FGRS. 














Adult effects of fetal IGF1 therapy for FGR 
34 


















IVGTT-AUCRG1R (mmol∙LP-1P) 192±10 191±10 186±10  169±4 174±4 169±4  ns ns 
IVGTT-AUCRG2R (mmol∙LP-1P) 855±71 891±65 783±52  894±67 945±67 840±64  ns ns 
Peak Δ Glucose (mmol∙LP-1P) 24.3±1.9 23.8±1.9 23.9±1.9  21.1±0.8 23.1±0.8 21.7±0.8  ns <0.05* 
IVGTT-AUCRI1R (ng∙mLP-1P) 27.4±4.1 18.6±4.1 17.0±6.4  17.6±2.9 19.6±2.0 16.5±2.0  ns ns 
IVGTT-AUCRI2R (ng∙mLP-1P) 218±48 175±44 139±59  196±42 218±41 189±41  ns ns 
Peak Δ Insulin (ng∙mLP-1P) 2.8±0.7 2.4±0.6 2.9±0.8  2.3±0.4 3.0±0.3 2.2±0.3  ns ns 
Δ IRS1 R(ng∙mLP-1P) 2.7±0.5 2.2±0.4 2.2±0.4  2.1±0.2 2.8±0.3 1.9±0.2  ns ns 
AIRR15 R(ng∙mLP-1P) 17.5±3.6 15.4±3.1 13.6±4.0  16.3±1.3 16.7±1.9 12.3±1.9  ns ns 
ln IRS R(ng∙mLP-1P∙mmol∙LP-1P) -1.7±0.4 -1.8±0.4 -1.8±0.4  -1.8±0.2 -1.6±0.2 -1.7±0.2  ns <0.05* 
Table 3. Glucose tolerance in adulthood. Intravenous glucose tolerance test (IVGTT) first (AUC-GR1R) and second (AUC-GR2R) phase 
glucose response, peak glucose change (Δ), first (AUC-IR1R) and second AUC-IR2R) phase insulin response, peak change (Δ) in insulin 
secretion, first phase insulin response change from baseline (Δ IRS1R), insulin response (AIR R15R), and insulin secretion (I RSR) throughout the 
test. Data are mean ± SEM. Symbols denote significant differences amongst experimental groups upon post hoc testing: * CON vs. FGRS. 
 
Adult effects of fetal IGF1 therapy for FGR 
35 


















HGC-AUCRISSR (ng∙mLP-1P) 109±48 114±46 163±48  75±7 93±11 64±11  ns ns 
HGC-AUCRIARGR (ng∙mLP-1P) 115±29 134±26 159±26  91±8 93±12 79±12  ns ns 
HGC-AUCRGSSR (mmol∙LP-1P) 596±6 594±6 592±6  599±3 602±3 598±3  ns ns 
HGC-AUCRGARGR (mmol∙LP-1P) 293±3 290±3 300±3  292±2 293±2 295±2  <0.05‡ ns 
IGRSSR (mg·kgP-1P·minP-1P) 7.6±0.9 6.0±0.9 9.6±1.0  7.0±0.9 7.2±0.6 6.4±0.6  <0.05‡ ns 
IGRARGR (mg·kgP-1P·minP-1P) 8.4±1.3 8.3±1.3 10.4±1.3  8.2±0.3 9.1±0.6 6.7±0.6  ns ns 
Mean IRSSR (ng∙mLP-1P) 2.3±1.1 2.5±1.1 3.3±1.1 
 1.6±0.3 1.9±0.3 1.5±0.3  ns ns 
Peak IRARGR (ng∙mLP-1P) 5.7±2.7 6.9±2.6 8.4±2.7  4.4±0.8 4.5±0.8 4.3±0.8  ns ns 
ΔIRsR ARG:SS 2.7±0.2 2.9±0.2 2.6±0.1  2.7±0.1 2.3±0.2 2.8±0.2  ns ns 
SRi RSS (mg∙kgP-1P∙minP-1P∙ng∙mLP-1P) 4.5±1.3 3.4±1.2 5.0±1.3  4.3±0.7 3.5±0.8 5.4±1.3  ns ns 
SRi RARG (mg∙kgP-1P∙minP-1P∙ng∙mLP-1P) 2.5±0.7 1.8±0.7 2.8±0.7  2.5±0.4 2.5±0.4 2.7±0.4  ns ns 
DIRGR (mg∙kgP-1P) 70.9±12.5 35.9±11.5 64.5±12.4 
 58.2±15.4 60.6±15.2 75.5±15.2  0.06* ns 
GSIS (ng∙mLP-1P) 1.9±0.6 1.9±0.6 2.2±0.6  1.3±0.3 1.6±0.2 1.1±0.2  ns ns 
Table 4. Glucose-mediated insulin response in adulthood. Absolute insulin and glucose responses to a hyperglycemic clamp (HGC): Area 
under the curve (AUC) for plasma insulin (I) and glucose (G) during steady state (HGC-AUCRISSR, HGC-AUCRGSSR) and in response to ˪-Arginine 
bolus (HGC-AUCRIARGR, HGC-AUGRIARGR), glucose infusion rate (IG) (mmol∙kg∙min P-1P) during steady state (IGRSSR) and in response to an ˪-Arginine 
bolus (IGRARGR), mean plasma insulin concentration (ng∙mL P-1P) during steady state (IRSSR) and peak plasma insulin concentration in response to an 
˪ -Arginine bolus (IRARGR), change in insulin secretion from steady state to the peak following the ˪-Arginine bolus (ΔIRSR), insulin sensitivity (SRiR), 
glucose disposition index (DI RGR), and glucose-stimulated insulin secretion (GSIS). Data are mean ± SEM. Symbols denote significant differences 
amongst experimental groups upon post hoc testing: * FGRS vs CON; † FGRI vs. CON; ‡ FGRI vs. FGRS.  
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 Female  Male  
Significance 
(treatment effect) 
 CON FGRS FGRI  CON FGRS FGRI  
Female Male 
  n=9 n=10 n=10  n=9 n=8 n=8  
EPI-AUCRG7.5R (mmol∙LP-1P) 5.6±0.5 5.7±0.5 6.2±0.4  6.0±1.0 5.3±1.0 4.0±1.1  ns <0.05† 
EPI-AUCRGT R (mmol∙LP-1P) 44.5±5.6 45.5±4.9 37.9±5.2  36.1±4.6 40.1±5.2 34.1±4.6  ns ns 
ln EPI-AUC RβHBA7.5R (mmol∙LP-1P) 0.4±0.1 0.3±0.1 0.3±0.1  0.3±0.2 0.3±0.1 0.5±0.1  ns ns 
ln EPI-AUCRβHBAT R(mmol∙LP-1P) 0.8±0.4 0.4±0.3 1.3±0.4  0.8±0.3 1.1±0.3 0.6±0.3  ns ns 
ln EPI-AUCRNEFA7.5R (mmol∙LP-1P) 1.1±0.3 1.1±0.2 0.7±0.3  1.1±0.2 1.1±0.2 0.9±0.2  ns ns 
ln EPI-AUCRNEFAT R (mmol∙LP-1P) 2.2±0.8 2.1±0.8 1.1±0.8  1.5±0.5 1.5±0.5 1.6±0.5  ns ns 
Glucose:NEFAR7.5 16.5±12.9 25.3±12.6 40.4±12.8  23.9±12.9 34.5±12.8 37.3±12.8  <0.05† ns 
βHBA:NEFA R7.5 1.1±1.4 1.8±1.4 3.9±1.4  1.5±1.1 2.8±1.1 3.0±1.1  <0.05†‡ ns 
Table 5. Adrenergic sensitivity. Absolute and natural log transformation (ln) of metabolite responses to epinephrine (EPI) stimulation: Area 
under the curve (AUC) for plasma glucose (G), β-hydroxybutyric acid (βHBA), and non-esterified fatty acids (NEFA) in the first 7.5 minutes 
(EPI-AUCRG7.5R, EPI-AUCRNEFA7.5 R, and EPI-AUCRβHBA7.5R) and 60 minutes (EPI-AUCRGTR, EPI-AUCRNEFATR, and EPI-AUCRβHBATR), and peak glucose and 
βHBA relative to NEFA response at 7.5 minutes. Data are mean ± SEM. Symbols denote significant differences amongst experimental groups 
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Supplementary Figure 1. Animals utilised during the project according to 23 
experimental group and sex. Dashed boxes report exclusions, deaths and 24 
euthanasia. Split boxes reporting postnatal deaths indicate the number of females 25 
(top left) and males (bottom right) for each experimental group. Circumstances 26 
constituting exclusion from the project and/or euthanasia were due to postnatal 27 
illness or paddock deaths. 28 
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Supplementary Figure 2. Plasma metabolite response to intravenous 30 
epinephrine injection. Plasma glucose, non-esterified fatty acids (NEFA), and β-31 
hydroxybutyric acid (βHBA) response to an intravenous epinephrine injection in 32 
female (A, C, E: CON, white, n=9; FGRS, grey, n=10; FGRI, black, n=10) and male 33 
(B, D, F: CON, white, n=9; FGRS, grey, n=9; FGRI, black, n=8) sheep. Data are 34 
mean ± SEM. Roman numerals denote the significant difference between 35 
experimental groups (RM ANOVA: i, effect of time, p<0.05; ii, time*experimental 36 
group interaction p<0.05). Symbols denote significant differences amongst 37 
experimental groups upon post hoc testing: ‡FGRS vs. FGRI p<0.05.  38 








Supplementary Table 1. Animal losses during experimental procedures.  Sheep 45 
excluded, euthanised, or found dead postnatally due to: °infection-related deaths 46 
(coccidiosis, n=2; eosinophilic gastroenteritis and hepatocellular atrophy, n=1; 47 
listeriosis, n=2; lymphocytic meningoencephalitis, n=1; pneumonia, n=4; 48 
rhododendron poisoning, n=1; umbilical infection, n=1), P●Pnon-specific pulmonary  49 
edema, n=1; ⁺ fight wounds, n=1.50 
  CON FGRS FGRI 
Postnatal illness  4° 4°, 1 P● 4° 
Paddock death    1⁺ 
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 Female Male 
BMC (g) 745±45 703±42 698±45  826±83 760±87 827±86  ns ns 
BMD (g·cmP-2P) 1.38±0.05 1.33±0.04 1.26±0.13  1.40±0.10 1.37±0.12 1.42±0.11  ns ns 
Chest LM (kg) 12.3±0.6 12.0±0.6 12.1±0.6  15.8±0.6 14.6±0.7 15.1±0.7  ns ns 
Chest FM (kg) 2.5±0.6 2.1±0.6 2.2±0.6  1.2±0.2 0.7±0.2 0.7±0.2  ns ns 
Abdominal LM (kg) 20.3±1.2 19.5±1.2 19.2±1.2  24.8±0.5 22.8±0.8 23.0±0.8  ns ns 
Abdominal FM (kg) 4.1±1.0 3.4±0.9 3.5±1.0  1.9±0.4 1.1±0.4 1.1±0.4  ns ns 
Rump LM (kg) 8.9±0.4 8.6±0.4 8.9±0.4  10.7±0.4 9.8±0.5 10.2±0.4  ns ns 
Rump FM (kg) 1.8±0.4 1.5±0.4 1.6±0.4  0.8±0.1 0.5±0.2 0.5±0.2  ns ns 
Total LM (%) 41.4±2.2 40.2±2.1 40.2±2.2  51.4±1.4 47.3±1.8 48.4±1.6  ns ns 
Total FM (%) 8.4±2.0 7.0±1.9 7.2±2.0  3.9±0.7 2.3±0.8 2.2±0.8  ns ns 
LM:WT (%) 70.0±1.5 70.5±1.3 73.1±1.7  75.8±1.0 76.7±1.3 76.2±1.2  ns ns 
FM:WT (%) 14.1±2.7 12.4±2.6 12.1±2.6  5.7±1.1 3.4±1.2 3.5±1.2  ns ns 
Chest FM:WT (%) 4.2±0.8 3.7±0.8 3.6±0.8  1.7±0.3 1.0±0.4 1.1±0.4  ns ns 
Abdominal FM:WT (%) 6.8±1.3 6.0±1.2 5.8±1.3  2.7±0.6 1.6±0.6 1.7±0.6  ns ns 
Rump FM:WT (%) 3.0±0.6 2.7±0.5 2.6±0.6  1.2±0.2 0.7±0.2 0.7±0.2  ns ns 
Abdominal FM:Total FM (%) 48.8±0.6 48.5±0.5 47.3±0.7  48.2±0.6 48.3±0.6 48.2±0.6  ns ns 
Supplementary Table 2. Body composition at 12 months of age. Bone mineral content (BMC), bone mineral density (BMD) 
compartmental and total lean mass (LM) and fat mass (FM), absolute and, where appropriate, relative to weight (WT). Data are mean ± 
SEM. 
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